What diseases does Ripretinib treat?

Ripretinib is effective and safe as a fourth-line (or further line) therapy in patients with advanced gastrointestinal stromal tumors. In May 2020, the U.S. FDA approved the use of repetitinib to treat adult patients with advanced gastrointestinal stromal tumors who have previously received three or more kinase inhibitors, including imatinib. The results of the INVICTUS study show that treatment with repetinib significantly improved the median progression-free survival.

Originally known as DCC-2618 and now trade name Qinlock, rapatinib was developed by Deciphera Pharmaceuticals to inhibit primary and drug-resistant secondary KIT and PDGFRA mutations. Ripetinib has activity against wild-type KIT and PDGFRA and a broad spectrum of KIT and PDGFRA mutations, including primary and resistance mutations in KIT exons 9, 11, 13, 14, 17 and 18, including the regorafenib-resistant D816V mutation, outperforming competing type I and type II inhibitors.

The original drug of Ripetinib has been marketed in China and has been approved by the National Medical Insurance Bureau to enter the scope of Class B medical insurance, but it is limited to patients who meet the indications. The price of each box of 50mg*30 tablets may be around 30,000 yuan. The expensive price may increase the pressure on families with heavy financial burdens. The US version of Ripetinib Specifications50mg*90 tablets sold overseas may be priced around RMB 77,000 per box (the price may fluctuate due to exchange rates). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. Currently, there is no generic drug of Ripetinib produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.